2530
S. An et al.
PAPER
2-(4-Bromophenyl)-1,4,5,6-tetrahydropyrimidine (3l)5g
2-(Pyrazin-2-yl)-1,4,5,6-tetrahydropyrimidine (3f)
Following the general procedure, the product was obtained by chro-
matography (silica gel, EtOAc–MeOH, 3:1; Rf = 0.35) to provide 3f
(3.12 mmol, 78%) as a white solid; mp 114–116 °C.
Following the general procedure, the product was obtained by chro-
matography (silica gel, EtOAc–MeOH, 3:1; Rf = 0.29) to provide 3l
(3.20 mmol, 80%) as a white solid; mp 155–156 °C.
IR (KBr): 3361, 2950, 2929, 2849, 1630, 1573, 1469, 1155, 774
cm–1.
IR (KBr): 3424, 3284, 3124, 2997, 2647, 1608, 1536, 1175, 727
cm–1.
1H NMR (400 MHz, CDCl3): δ = 9.41 (s, 1 H), 8.60 (d, J = 2.3 Hz,
1 H), 8.44 (d, J = 1.2 Hz, 1 H), 3.58 (s, 4 H), 1.87–1.91 (m, 2 H).
1H NMR (400 MHz, CD3OD): δ = 7.68 (d, J = 7.2 Hz, 2 H), 7.56 (d,
J = 8.0 Hz, 2 H), 3.51 (t, J = 4.0 Hz, 4 H), 1.99 (m, 2 H).
13C NMR (101 MHz, CDCl3): δ = 150.53, 146.87, 145.10, 143.13,
13C NMR (101 MHz, CD3OD): δ = 159.57, 133.12, 129.88, 127.10,
141.85, 35.80, 20.66.
41.51, 20.16.
MS (EI): m/z = 162 [M]+.
MS (EI): m/z = 238 [M]+.
HRMS (ESI): m/z [M + H]+ calcd for C8H11N4: 163.0984; found:
163.1038.
2-(1,4,5,6-Tetrahydropyrimidin-2-yl)benzonitrile (3m)
Following the general procedure, the product was obtained by chro-
matography (silica gel, EtOAc; Rf = 0.35) to provide 3m (3.76
mmol, 94%) as a white solid; mp 142–144 °C.
2-(Thiophen-2-yl)-1,4,5,6-tetrahydropyrimidine (3g)6b
Following the general procedure, the product was obtained by chro-
matography (silica gel, EtOAc–MeOH, 3:1; Rf = 0.26) to provide
3g (3.40 mmol, 85%) as a yellow solid; mp 185–186 °C.
IR (KBr): 3429, 3211, 2957, 2851, 1643, 1472, 1427, 1360, 1093,
774, 712 cm–1.
IR (KBr): 3193, 3012, 2934, 2832, 1606, 1549, 1514, 1325, 1167,
712 cm–1.
1H NMR (400 MHz, CDCl3): δ = 7.35 (d, J = 4.0 Hz, 2 H), 7.03 (dd,
J = 6.4, 2.3 Hz, 1 H), 3.51 (t, J = 5.7 Hz, 4 H), 1.92–1.88 (m, 2 H).
1H NMR (400 MHz, CDCl3): δ = 7.89 (dd, J = 3.9, 2.6 Hz, 1 H),
7.76 (d, J = 3.2 Hz, 1 H), 7.64–7.58 (m, 2 H), 3.87 (t, J = 6.0 Hz, 2
H), 3.79 (t, J = 5.6 Hz, 2 H), 2.09–2.02 (m, 2 H).
13C NMR (101 MHz, CDCl3): δ = 160.54, 151.90, 133.75, 131.74,
131.42, 130.80, 121.19, 120.76, 45.26, 37.59, 20.29.
MS (EI): m/z = 185 [M]+.
13C NMR (101 MHz, CDCl3): δ = 150.35, 140.50, 127.72, 127.19,
124.69, 41.83, 20.59.
MS (EI): m/z = 166 [M]+.
HRMS (ESI): m/z [M + H]+ calcd for C11H12N3: 186.1026; found:
186.1092.
3-(1,4,5,6-Tetrahydropyrimidin-2-yl)aniline (3i)22
Following the general procedure, the product was obtained by chro-
matography (silica gel, EtOAc–MeOH, 3:1; Rf = 0.30) to provide 3i
(2.60 mmol, 65%) as a yellow oil.
3-(1,4,5,6-Tetrahydropyrimidin-2-yl)benzonitrile (3n)7c
Following the general procedure, the product was obtained by chro-
matography (silica gel, EtOAc; Rf = 0.33) to provide 3n (3.80
mmol, 95%) as a white solid; mp 136–137 °C.
IR (KBr): 3308, 3208, 3125, 2996, 1644, 1629, 1593, 1495, 1046,
791, 719 cm–1.
1H NMR (400 MHz, DMSO): δ = 7.20 (t, J = 8.0 Hz, 1 H), 6.85–
6.80 (m, 3 H), 5.59 (s, 2 H), 3.43 (t, J = 4.0 Hz, 4 H), 1.94–1.92 (m,
2 H).
13C NMR (101 MHz, DMSO): δ = 162.67, 151.91, 132.26, 132.13,
120.69, 116.87, 114.40, 41.31, 20.45.
IR (KBr): 3424, 3117, 2996, 2777, 2233, 1648, 1617, 1449, 1103,
884, 807, 710 cm–1.
1H NMR (400 MHz, CDCl3): δ = 7.98 (s, 1 H), 7.91 (d, J = 7.8 Hz,
1 H), 7.68 (d, J = 7.6 Hz, 1 H), 7.50 (m, 1 H), 3.53 (t, J = 5.7 Hz, 4
H), 1.91–1.85 (m, 2 H).
13C NMR (101 MHz, CDCl3): δ = 153.09, 138.37, 132.84, 130.55,
130.08, 129.11, 118.51, 112.14, 42.17, 20.48.
MS (EI): m/z = 185 [M]+.
MS (EI): m/z = 175 [M]+.
2-(4-Chlorophenyl)-1,4,5,6-tetrahydropyrimidine (3j)6b
Following the general procedure, the product was obtained by chro-
matography (silica gel, EtOAc–MeOH, 3:1; Rf = 0.36) to provide 3j
(3.20 mmol, 80%) as a white solid; mp 124–128 °C.
4-(1,4,5,6-Tetrahydropyrimidin-2-yl)benzonitrile (3o)7c
Following the general procedure, the product was obtained by chro-
matography (silica gel, EtOAc; Rf = 0.40) to provide 3o (3.80
mmol, 95%) as a white solid; mp 69–71 °C.
IR (KBr): 3178, 2952, 2853, 1623, 1541, 1488, 1194, 1036, 836
cm–1.
1H NMR (400 MHz, CDCl3): δ = 7.61 (d, J = 6.7 Hz, 2 H), 7.35 (d,
J = 8.1 Hz, 2 H), 3.51 (t, J = 4.0 Hz, 4 H), 1.92–1.85 (m, 2 H).
13C NMR (101 MHz, CDCl3): δ = 154.69, 135.76, 134.83, 128.35,
127.70, 41.76, 20.31.
IR (KBr): 3431, 3052, 2361, 2232, 1630, 1504, 1401, 1199, 845
cm–1.
1H NMR (400 MHz, CDCl3): δ = 7.79 (dd, J = 8.2, 3.6 Hz, 2 H),
7.68 (dd, J = 8.3, 4.2 Hz, 2 H), 3.54 (t, J = 4.0 Hz, 4 H), 1.92–1.85
(m, 2 H).
13C NMR (101 MHz, CDCl3): δ = 153.29, 141.47, 132.10, 126.89,
118.57, 112.97, 42.27, 20.45.
MS (EI): m/z = 194 [M]+.
2-(4-Nitrophenyl)-1,4,5,6-tetrahydropyrimidine (3k)6b
Following the general procedure, the product was obtained by chro-
matography (silica gel, EtOAc–MeOH, 3:1; Rf = 0.42) to provide
3k (3.80 mmol, 95%) as a yellow solid; mp 140–142 °C.
MS (EI): m/z = 185 [M]+.
3-(4,5-Dihydro-1H-imidazol-2-yl)pyridine (5a)6f
Following the general procedure, the product was obtained by chro-
matography (silica gel, EtOAc–MeOH, 3:1; Rf = 0.35) to provide
5a (3.44 mmol, 86%) as a white solid; mp 102 °C.
IR (KBr): 3424, 3179, 2936, 2854, 1625, 1598, 1521, 1487, 1343,
1107, 861, 810 cm–1.
IR (KBr): 3160, 2938, 2854, 1609, 1587, 1513, 1485, 1277, 984,
706 cm–1.
1H NMR (400 MHz, DMSO): δ = 9.02 (s, 1 H), 8.66 (d, J = 3.6 Hz,
1 H), 8.18 (d, J = 7.8 Hz, 1 H), 7.48 (dd, J = 7.3, 5.0 Hz, 1 H), 3.65
(s, 4 H).
1H NMR (400 MHz, CDCl3): δ = 8.25 (d, J = 8.7 Hz, 2 H), 7.87 (d,
J = 8.7 Hz, 2 H), 3.57 (t, J = 5.7 Hz, 4 H), 1.92 (m, 2 H).
13C NMR (101 MHz, CDCl3): δ = 152.95, 148.47, 143.10, 127.17,
123.55, 42.39, 20.44.
MS (EI): m/z = 205 [M]+.
Synthesis 2013, 45, 2525–2532
© Georg Thieme Verlag Stuttgart · New York